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Abstract: Ultra-small superparamagnetic particles of iron oxide (USPIO) are iron-oxide based 
contrast agents that enhance and complement in vivo magnetic resonance imaging (MRI) by 
shortening T1, T2, and T2* relaxation times. USPIO can be employed to provide immediate 
blood pool contrast, or to act as subsequent markers of cellular inflammation through uptake by 
inflammatory cells. They can also be targeted to specific cell-surface markers using antibody 
or ligand labeling. This review will discuss the application of USPIO contrast in MRI studies 
of cardiovascular disease.
Keywords: cardiac, aortic, MRI, USPIO, carotid, vascular, molecular imaging
Introduction
Beyond the anatomical and morphological information afforded by standard clini-
cal cardiovascular imaging techniques, it is increasingly recognized that additional 
information regarding the underlying biological processes involved would be valuable 
in a range of cardiovascular diseases to aid understanding of disease pathogenesis, 
provide diagnostic information, predict disease progression, and to monitor response 
to treatment. Novel molecular and cellular imaging techniques can identify metabolic 
and biological processes that are critical to disease pathogenesis, and therefore have 
the potential to predict clinical events and guide therapeutic intervention.
A range of potential imaging modalities exists (Table 1). Magnetic resonance 
imaging (MRI) has a number of advantages including excellent discrimination of 
soft tissue components, good spatial resolution and avoidance of ionizing radiation, 
a particular consideration if serial imaging is envisaged.
Iron oxide particles are a group of MRI contrast agents that can be used for vascular, 
molecular and cellular imaging.1 Iron oxide particles can be categorized according to 
their size: nano-sized very small superparamagnetic particles of iron oxide (VSPIO, 
,20 nm in diameter), ultra-small superparamagnetic particles of iron oxide (USPIO, 
20–50 nm in diameter), small superparamagnetic particles of iron oxide (SPIO, 
60–250 nm in diameter), and micro-sized particles of iron oxide (MPIO, 1–8 µm in 
diameter). VSPIO and USPIO are often classified together (as USPIO) due to similar 
size. Superparamagnetism occurs when the size of the iron oxide crystal is smaller 
than that of ferromagnetic domains (approximately 30 nm). Under the influence of a 
strong external magnetic field, such as within an MRI scanner, iron oxide nanoparticles 
have a large magnetic moment, but unlike larger ferromagnetic particles, this magnetic 
moment is lost when the field is removed.
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Figure 1 Patient imaged 3 days after an anterior myocardial infarct with T2*-
weighted magnetic resonance imaging.
Notes: images show T2* maps of baseline pre-iron scan (A), and 24 hours following 
ferumoxytol (USPiO) administration (B). iron uptake is seen as signal void (dark) in 
the region of the anterior infarct (arrow).
Abbreviation: USPiO, ultra-small superparamagnetic particles of iron oxide.
Table 1 Summary of commonly used molecular imaging modalities
Modality Spatial resolution Temporal resolution Sensitivity Penetration Radiation Cost
MRi 10–100 micron High Low Good No High
US 50 micron High Medium cm No Medium
SPeCT 1–2 mm Low Medium Good Yes Medium
PeT 1–2 mm Low High Good Yes High
Fluorescence 2–3 mm High High ,1 cm Yes/no Low
Abbreviations: MRi, magnetic resonance imaging; US, ultrasound; SPeCT, single-photon emission computerised tomography; PeT, positron emission tomography.
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USPIO generally consist of an iron oxide core surrounded 
by a coating, usually of carbohydrate or polymer construc-
tion, with a total particle diameter of less than 50 nm. The 
purpose of the coating is to prevent aggregation, to retain 
particles within a colloidal suspension and to provide a sur-
face for conjugation of drug molecules and targeting ligands. 
A range of particles exists varying in size and coating; these 
two properties are the key determinants of biodistribution, 
magnetic behavior, and thus the potential applications of the 
particle.2,3 The majority of proposed applications for iron 
oxide nanoparticles utilize particles within the ultra-small 
and small size ranges.
Following administration, cells of the reticuloendothelial 
system including inflammatory macrophages internalize iron 
oxide nanoparticles. Neutrophils and structural endothelial 
and tumor cells also take up iron nanoparticles. Larger SPIO 
particles are identified and rapidly engulfed, principally by 
resident macrophages in the lymphoreticular organs including 
the liver, spleen, and lymph nodes. In contrast, USPIO par-
ticles are much smaller and therefore less readily recognized 
by cells, escaping immediate phagocytosis and resulting in 
a much longer half-life within the blood pool compared to 
larger particles (up to 36 hours for USPIO4 versus as low as 
2 hours for larger SPIO5 in humans). The biodistribution of 
USPIO is individual to each particle but a blood pool half-life 
of several hours is expected with distribution predominantly 
in the spleen, liver, bone marrow, and lymph nodes, before 
being cleared within a matter of a few days. Cytotoxicity data 
for iron nanoparticles is limited but is not found until exposure 
to high levels of iron and is also dependent on factors such as 
surface coating or its breakdown products, composition of the 
cell medium, and protein-iron nanoparticle interaction.6–9
Whilst circulating within the blood pool, USPIO are 
small enough to migrate passively across the endothelium1 
especially in regions of the vasculature where there is 
loss of endothelial integrity. Once present within tissues, 
nanoparticles are concentrated and engulfed by resident 
macrophages through phagocytosis and pinocytosis resulting 
in their concentration within inflamed tissues. This concen-
tration results in magnetic cooperativity, enhancing their 
superparamagnetic effects, markedly shortening the T2* 
relaxation time and creating local signal deficits on T2- and 
T2*-weighted images. Thus USPIO can highlight areas of 
tissue inflammation on MRI.10
Earlier studies using iron nanoparticles employed semi-
quantitative methods to calculate reduction in signal intensity 
consistent with iron accumulation, however this is liable 
to variations in signal across the image relative to proxim-
ity to surface coils between visits, and also assumes that 
signal intensity in the control tissue is consistent between 
both pre- and post-USPIO scans. Calculation of changes in 
T2 and T2* relaxivity values has been adopted for a more 
sensitive and objective approach. The T2 and T2* relaxivity 
values, are the initial decay constants for the exponential 
decay of signal intensity with increasing echo time. Calcula-
tion and comparison of decay constants for each region of 
interest allows for a more objective and quantitative analysis 
approach and thus accounts for problems caused by varia-
tions in relaxivity values between regions and also MRI coil 
sensitivity between subject visits. In the presence of USPIO 
the signal decays more rapidly and the T2 and T2* relaxivity 
values are reduced. On the resulting images, particularly on 
T2*-weighted images, a profound reduction in signal inten-
sity is evident as a region of signal void (hypointense region) 
where USPIOs have accumulated (Figure 1).
Precise blood suppression during USPIO-enhanced MRI 
is important to reduce artifact into nearby myocardium, 
Journal of Vascular Diagnostics 2014:2
Table 2 Summary of USPiO studies discussed in this article
Agent name Iron oxide cored  
diameter, nm  
(total diameter)
Coating Magnet  
strength
Administration  
site
Clinical/ 
preclinical
Application Reference
Ferumoxtran-10
(AMi-227,  
Combidex®, 
Sinerem®)
6.3 (35) Dextran 1.5 T 
1.5 T 
 
7 T 
1.5 T 
1.5 T 
 
1.5 T 
1.5 T 
1.5 T 
3 T 
1.5 T
intravenous 
intravenous 
 
intramyocardial 
intravenous 
intravenous 
 
intravenous 
intravenous 
intravenous 
intravenous 
intravenous
Clinical 
Preclinical 
 
Preclinical 
Preclinical 
Clinical 
 
Clinical 
Clinical 
Clinical 
Clinical 
Clinical
Ventricular contrast 
Cardiac transplant  
rejection 
Stem cells 
Atherosclerosis 
Atherosclerosis 
 
Atherosclerosis + AAA 
Aortic + iliac aneurysms 
AAA 
AAA 
Lymph node metastases
11 
26,28 
 
36 
50,51 
52–55, 
57–59,62 
76 
77 
78 
79 
80
NC100150 
(Clariscan™)
6.43 (20) Dextran 0.5/1.5 T 
1.5 T 
1.5 T 
1.5 T 
2 T 
1.5 T
intravenous 
intravenous 
intravenous 
intravenous 
intravenous 
intravenous
Clinical 
Preclinical 
Clinical 
Preclinical 
Preclinical 
Preclinical
Ventricular contrast 
Coronary contrast 
Coronary contrast 
Myocardial contrast 
Myocardial contrast 
Cardiac transplant  
rejection
12–15 
16 
17,18 
19,20 
21 
25,26
n/a n/a (27) Dextran 4.7 T intravenous Preclinical Cardiac transplant  
rejection
24,27
n/a 6 (n/a) Polymer 1.5 T intravenous Preclinical Cardiac allograft  
rejection
30
n/a (CLiO) 3–5 (15–20) Dextran 9.4 T 
9.4 T 
1.5 T 
 
n/a 
9.4 T
intravenous 
intramyocardial 
Gel Phantom/ 
intramyocardial 
n/a (in-vitro) 
intravenous
Preclinical 
Preclinical 
in vitro/ 
ex vivo 
in vitro 
Preclinical
Myocardial infarction 
Stem cells 
Stem cells 
 
Apoptosis 
Apoptosis
32 
37 
39 
 
40 
41,42
Ferumoxytol 
(Rienso®, 
Feraheme®)
3.25 (17–31) Dextran 3 T 
1.5 T
intravenous 
intravenous
Clinical 
Clinical
Myocardial infarction 
Myocardial infarction
33 
34
n/a n/a (7.5) Amine silane 3 T intracoronary Preclinical Stem cells 38
n/a 2–7 (15–40) Polysaccharide 1.5 T intravenous Preclinical Atherosclerosis 49
Note: Rienso®; Takeda italia S.p.A, Rome, italy.
Abbreviations: USPiO, ultra-small superparamagnetic particles of iron oxide; AAA, abdominal aortic aneurysms; CLiO, cross-linked particles of iron oxide; n/a, not available.
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which is often the region of interest under examination. 
 Magnetization transfer between the blood pool and myocar-
dium, and also flow-related blood pool artifact, may compro-
mise the quality of T2* data. Double inversion techniques 
are commonly used to suppress blood signal in most cardiac 
MRI examinations. However, double inversion techniques 
do not account for changes in blood pool USPIO related T1 
shortening. Therefore, more complicated inversion strategies 
(such as a quadrature inversion technique) may be required 
to fully null blood signal in both pre- and post-USPIO data, 
although these inversion techniques are less commonly avail-
able on clinical systems and so are not widely used.
Here, we focus on the use of USPIO in cardiovascu-
lar imaging, discussing their application as a blood pool 
contrast agent, a tracer highlighting inflammatory cells of 
the  reticuloendothelial system, and in targeted imaging 
 conjugated to a specific antibody or peptide (Table 2).
Cardiac imaging
Blood pool contrast
USPIO have been used successfully as coronary and ventricular 
MRI blood pool contrast agents for over a decade as they have 
longer blood pool circulating time compared to standard MRI 
angiographic agents such as gadolinium. In 1997, Stillman 
et al11 demonstrated improved myocardial to blood pool bor-
der definition with ferumoxtran-10 on T1-weighted MRI cine 
images. Image intensity gradients at the myocardial to blood 
pool interface increased significantly in both long and short axis 
views. At the time it was thought that ferumoxtran-10 would 
improve automated ventricular cavity edge detection.
Journal of Vascular Diagnostics 2014:2submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
102
Stirrat et al
This was soon followed up by Taylor et al12 who used an 
alternative USPIO agent, NC100150 (ClariscanTM) with a 
blood pool half-life of over 2 hours, to aid ventricular cavity 
edge detection using MRI. They administered NC100150 
to 18 healthy male volunteers and examined optimized cine 
imaging sequences. At higher doses (3 and 4 mg Fe/kg) 
a reduction in signal intensity was seen in the blood pool 
enabling enhanced detection of the left ventricle blood pool 
to myocardial interface thus improving functional assessment 
of the left ventricle. The finding that NC100150 improves 
myocardial blood pool definition has since been repeated in 
other human studies.13–15
NC100150 has been used extensively as a coronary 
contrast agent for MRI coronary angiography (MRCA) with 
mixed results. Johansson et al compared invasive X-ray 
angiography with T1-weighted MRCA using NC100150 in 
pigs with coronary artery stenosis.16 Although the sample 
size was small (n=6), the location and severity grading of 
stenoses on MRCA correlated well with X-ray angiography 
findings in all animals. Within a few years, Sandstede et al17 
carried out a feasibility study using the same contrast agent 
in patients with coronary artery disease. Proximal segments 
of coronary arteries could be visualized but distal visual-
ization was poor. Furthermore, no improvement in image 
quality was seen when an increased USPIO dose was used 
and only six of eight proximal coronary stenoses seen on 
conventional angiography were detected on the NC100150 
contrast enhanced scan.
Klein et al18 conducted an experiment comparing 
NC100150 enhanced MRI with unenhanced MRI imaging, 
again yielding mixed results. Although the visible length of 
mid and distal portions of the coronary artery improved on 
USPIO-enhanced imaging, there was no improvement when 
assessing the proximal portion of the artery. Furthermore, 
only eight of the eleven significant coronary stenoses (.50%) 
were detected on USPIO-enhanced MRI compared to six on 
the unenhanced scan.
Soon after the development of USPIO as a blood 
pool contrast agent for ventricular cavity and coronary 
imaging, attempts were made to illustrate myocardial 
viability with conflicting results. Kroft et al19 administered 
 ferumoxtran-10 (AMI-227, Sinerem®) in a pig model 
of myocardial infarction (MI) and then imaged using 
T1-weighted MRI with a 1.5 T scanner. Interim imaging 
failed to detect USPIO in the viable myocardium, likely due 
to low dose, fast elimination time of the contrast agent, and 
a low field strength scanner. Increasing the magnetic field 
strength provides improved signal-to-noise ratio, greater 
spatial resolution, and higher sensitivity for detecting 
lower concentrations of iron, which is advantageous in the 
detection of USPIO.
Bjerner et al20 had more success using NC100150 in a 
similar model. Using T1-, T2-, and T2*-weighted imaging, 
they found that T1-weighted MRI with doses of 4 and 8 mg 
Fe/kg produced the best evaluation of perfused myocardium 
after histological validation against areas of fluorescein stain 
uptake on ex vivo histological analysis.
The use of USPIO as a myocardial tissue contrast agent 
was extended to a model of ischemia-reperfusion in rats to 
evaluate microvascular injury in reperfused myocardium. 
Krombach et al21 employed coronary ligation for 45 minutes 
and 3 hours of reperfusion, and administered NC100150, to 
help define regions of microvascular injury and obstruction 
after MI. USPIO distributes by diffusion in the extravas-
cular space of injured myocardium with damaged, leaky 
vasculature. They found that USPIO-enhanced imaging 
provided some indication of transmural and non-transmural 
microvascular injury. This imaging approach tended to 
overestimate the area of true infarction when compared to tri-
phenyltetrazolium chloride stain, and underestimate the area 
of myocardium deemed “at risk” of infarction determined 
by redo coronary ligation and intravenous phthalocyanine 
blue dye injection.
Inflammation
Endomyocardial biopsy is the “gold standard” diag-
nostic investigation for inflammatory diseases of the 
 myocardium. This does carry the potential for life-threatening 
complication,22 and sampling error is common due to the 
focal nature and spatial heterogeneity of underlying inflam-
matory processes. This procedure is rarely performed outside 
specialist tertiary referral centers.
Transplant rejection
Cardiac transplantation is a life prolonging treatment option 
for end-stage cardiac disease. Transplant rejection is a major 
threat to the allograft, occurring in 20%–30% of recipients in 
the first year.23 Rejection can occur at any stage after trans-
plantation and causes significant morbidity and  mortality. 
Serial surveillance myocardial biopsies are routinely under-
taken as rejection is notoriously difficult to diagnose using 
existing non-invasive imaging methods.
Kanno et al24 exploited the finding that iron nanopar-
ticles accumulated within the cytoplasm of macrophages, 
and detected organ rejection using MRI and dextran-coated 
USPIO in rats with evidence of cardiac allograft rejection. 
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Histopathology confirmed active rejection and identified 
USPIO uptake confined to macrophages that had accumulated 
within the rejecting cardiac allograft. Rats that received more 
prolonged immunosuppression had a decline in the rate of 
signal intensity reduction, suggesting less inflammation and 
indicating that treatment response could be monitored with 
this method.
Subsequent studies have confirmed the value of using 
USPIO to detect acute cardiac rejection in rats,25–27 although 
ferumoxtran-10 proved inferior to NC100150 at detecting 
rejection26 and was unable to detect acute cardiac rejection 
in rats in another study.28 In the latter study, ferumoxtran-10 
was given at two doses of 2 mg and 11 mg Fe/kg with T2*-
weighted MRI conducted using a 1.5 T scanner at postop-
erative day 7, 24 hours after USPIO administration. The 
failure to detect USPIO was thought to be due to the low 
field strength magnet of the MRI scanner.
Iron oxide particles can be conjugated to a specific anti-
body or peptide to target pathophysiological processes.29 
Recent work by Guo et al30 targeted T cells that play a cen-
tral role in acute cardiac allograft rejection. They built on 
work performed using ligand targeting of cells to employ a 
“theranostic” strategy, combining diagnostic imaging with 
administration of therapy within the one system (Figure 2). 
They targeted T cells in the endocardium of rejecting rat 
hearts using a CD-3 antibody-targeted multifunctional poly-
meric nanocarrier. This polyplex nanoparticle was further 
conjugated to a therapeutic gene (pDNA-DGKalpha) enabling 
simultaneous imaging and immune modulation of CD-3 
expressing T cells.
Mi
The development of cross-linked particles of iron oxide 
(CLIO)31 allowed targeted cardiac inflammatory imaging. 
Cross-linking and amination of the USPIO dextran chains 
encourages circumferential adherence of the dextran coat 
to the iron nanoparticle providing chemical stability and 
improved conjugation.31 Sosnovik et al32 conjugated CLIO 
with cyanine 5.5 dye creating a “magnetofluorescent” particle 
allowing co-registration of MRI and fluorescence molecular 
tomography data. They administered CLIO-Cy5.5 48 hours 
after left coronary artery ligation in a mouse model of MI 
with dual modality imaging 48 hours later. The accumulation 
of CLIO-Cy5.5 within infarcted regions of myocardium was 
clearly seen on fluorescence and MRI images that were not 
present on control mice (mice injected with CLIO-Cy5.5 but 
a “sham” operation). In vivo imaging findings were subse-
quently confirmed with histology. Examination of infarcted 
myocardium revealed a high degree of co-localization 
between inflammatory cell infiltrates on hematoxylin and 
eosin staining, increased signal intensity on fluorescence 
microscopy, and an abundance of macrophages on immu-
nohistochemistry staining. This is consistent with uptake 
of CLIO-Cy5.5 by macrophages infiltrating the infarcted 
myocardium.
Clinical applications of USPIO in highlighting myocardial 
inflammation after MI have since emerged following the dis-
covery that inflammation around the time of MI affects both 
the extent of myocardial salvage and recovery of left ventricular 
function. Our group33 used USPIO to image myocardial inflam-
mation following acute MI. Within 48 hours following acute 
MI, patients underwent MRI scanning at baseline (pre-USPIO) 
before receiving an infusion of ferumoxytol (USPIO) with 
subsequent serial MRI scans thereafter. The infarct zone was 
defined by delayed enhancement with gadolinium.  Following 
scAb-CD3-PEG-
PEI-SPION
Native
heart
Transplanted
heart
T-cell
ScAb-
CD3 PEG PEI SPION pDNA
Fluorescent
agent
CD3/TCR
complex
Figure 2 Schematic diagram of therapeutic process of magnetic targeting polyplex 
scAbCD3-PeG-g-Pei-SPiON in vitro and in vivo.
Notes: Reprinted with permission from Guo Y, Chen w, wang w, et al. 
Simultaneous diagnosis and gene therapy of immuno-rejection in rat allogeneic heart 
transplantation model using a T-cell-targeted theranostic nanosystem. ACS Nano. 
2012;6(12):10646–10657. Copyright © 2012 American Chemical Society.30 
Abbreviations: ScAb-CD3, CD3 single chain antibody; PeG, polyethylene glycol; 
Pei, polyethylenimine; SPiON, superparamagnetic iron oxide nanoparticles; pDNA, 
Plasmid DNA; TCR, T-cell receptor.
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USPIO administration, there was a significant increase in 
R2* (R2* = 1/T2*) in the infarct zone, with smaller changes 
observed in the peri-infarct zone (surrounding areas of delayed 
enhancement) and even in remote myocardium when com-
pared with control tissue (skeletal muscle). This suggested 
peri-infarct and remote myocardial inflammation, although 
no histological data were available to confirm this. Notably, 
the R2* value was greatest 24 hours following USPIO (feru-
moxytol) infusion, and had declined by 48 hours suggesting 
that 24 hours post-infusion is a more sensitive imaging time 
than 48 hours post-infusion in this group of patients.
Yilmaz et al34 also detected a reduction in T2* value in 
the infarct as well as in the peri-infarct region, the remote 
myocardium, and the lymphoreticular system. On imag-
ing the first three patients at 6, 24, 48 and 96 hours after 
ferumoxytol administration, they attempted to find the opti-
mal time window to characterize inflammation within the 
 myocardium. From these data, they suggest that signal attenu-
ation was maximal at 24 hours but that the best combination 
of T2-weighted (hypoenhancement seen) and T2*-weighted 
images was obtained at 48 hours.
Histological data are required to address the outstand-
ing question regarding distribution of USPIO within the 
myocardium and the relative contribution to changes in T2* 
of extracellular iron accumulating within the interstitium, 
capillary bed, and inflammatory macrophages.
The finding of T2* signal void in remote myocardium 
suggests a pan-myocardial inflammatory response in the 
context of a focal infarct. Grieve et al35 confirmed this finding 
in remote segments in a rat model of ischemia-reperfusion 
injury examining endovascular inflammation using a targeted 
larger iron oxide tracer (MPIO).
Other cardiac imaging
Stem cells
Current research endeavors are increasingly focusing on 
stem cell therapy following the discovery that pluripotent 
progenitor cells bear the capacity to differentiate into mature 
cardiac cells, in an attempt to restore function to organs with 
no regenerative capacity. There is a need to track stem cells 
following administration so that their distribution and fate 
can be determined. Cell labeling with iron nanoparticles is 
relatively simple, fast, inexpensive and is well described, 
although there have been few published studies using USPIO 
in cardiac stem cell imaging. Tracking of stem cells labeled 
with iron nanoparticles using MRI is still at the pre-clinical 
stage but offers high spatial resolution, excellent soft tissue 
detail, and avoids exposure to ionizing radiation.
Küstermann et al36 labeled cardiac progenitor cells 
expressing enhanced green fluorescent protein with 
 ferumoxtran-10 and implanted the cells into murine myo-
cardium injured through cryocoagulation or coronary 
artery  ligation. Co- registration of USPIO and stem cells 
was confirmed by comparing high-resolution MRI images 
with Prussian Blue stain for iron on histology, and immuno-
histochemistry for enhanced green fluorescent protein. Dif-
ficulties were encountered using this approach as the signal 
attenuation of unlabeled ischemic myocardium was similar 
to that induced by USPIO-labeled cells in T2*-weighted 
images making detection of labeled cells within infarcted 
regions difficult. However, the authors subsequently found 
that the combination of proton density- and T2*-weighted 
MRI sequences identified regions of myocardial injury and 
USPIO-labeled cells respectively – the larger area of signal 
attenuation in the T2*-weighted images was caused by infil-
tration of the iron-labeled cells.
Chapon et al37 combined MRI and positron emission 
tomography to track transplanted stem cells after MI in rats 
providing anatomical, physiological, and metabolic informa-
tion. They conjugated rat bone marrow-derived stem cells to 
CLIO and fluorescein dye enabling co-localization of stem 
cells to be assessed by in vivo MRI and ex vivo magnetic 
resonance  spectroscopy. Stem cells were successfully detected 
on MRI and histology for the 6 week duration of the study, 
however positron emission tomography signs of metabolic 
activity (18F-fluorodeoxyglucose uptake) was only seen in the 
first week post-stem cell implantation. This may have been due 
to early, localized inflammation from stem cell injection or 
more likely death of the stem cells. A trend to an improvement 
in cardiac function was found after stem cell implantation, 
although this did not reach statistical significance.
Ma et al38 compared the ability of USPIO and MPIO in 
tracking stem cells via intracoronary injection, as opposed to 
a direct intramyocardial route, in a swine model of ischemia-
reperfusion injury. They found that similar labeling efficiency 
was found in both particles, and differentiation and prolif-
eration of mesenchymal stem cells (MSCs) in vivo were 
not affected by labeling with either iron particle, confirmed 
by immunohistochemical assays showing similar protein 
expression. Hypointensity was seen in infarcted regions with 
both particles on T2*-weighted MRI at 4 and 8 weeks and 
co-localized with regions of iron uptake seen on Prussian 
Blue staining. However there was no hypointensity detected 
in 2/7 of the MPIO labeled pigs and the authors suggested 
that USPIO labeling was more suited to intracoronary injec-
tion than the larger MPIO particle.
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Mathiasen et al39 recently sought to determine the MRI 
detection limits of CLIO labeled human MSCs using gel-
phantoms in a clinical 1.5 T MR scanner. They determined 
the detection limit to be 250,000 MSCs using a 21 hours’ 
incubation time and 10 µg USPIO/105 MSCs. At lower incu-
bation times and doses of USPIO, significantly more cells 
were needed for detection. They confirmed their findings 
in ex vivo porcine myocardium by visualizing the USPIO-
labeled MSCs.
USPIO-enhanced MRI appears well placed to provide 
future clinical research opportunities to detect and track stem 
cells following implantation. However, to enhance sensitiv-
ity, detection limits for stem cell number and administered 
iron concentration for a particular MRI scanner would need 
to be determined in advance.
Apoptosis
During apoptosis, or programmed cell death, the phospho-
lipid phosphatidylserine is externalized on the cell surface. 
Annexin V is an endogenous protein that binds with high 
affinity to phosphatidylserine, and when conjugated to CLIO, 
has successfully been able to identify apoptotic cells in vitro 
using MRI.40 Sosnovik et al41 used this particle as a founda-
tion to create a multimodal nanoparticle further conjugated 
to cyanine 5.5 dye – AnxCLIO-Cy5.5 – allowing co-identifi-
cation with fluorescence microscopy and T2*-weighted MRI. 
In a murine model of ischemia reperfusion injury, a reduction 
in signal intensity on T2*-weighted imaging was observed in 
reperfused regions with AnxCLIO-Cy5.5 but not with unla-
beled CLIO-Cy5.5 suggesting uptake of AnxCLIO-Cy5.5 
within the injured and apoptotic myocardium. The area of 
signal loss correlated with the region of contractile dysfunc-
tion seen on MRI, and subsequently with areas of increased 
fluorescence intensity on near infra-red fluorescence.
More recently, Sosnovik et al employed a similar approach 
in developing a novel dual-contrast molecular MRI probe 
capable of detecting cardiomyocyte apoptosis and necrosis 
in mice with ischemia reperfusion injury in vivo.42 Using the 
same AnxCLIO-Cy5.5 particle to identify cellular apoptosis 
on MRI 4–6 hours after ischemia-reperfusion injury, they 
also administered a novel magnetofluorescent gadolinium 
chelate with subsequent gadolinium delayed enhancement 
MRI to illustrate necrosis. Interestingly, they found that 
only 21% of apoptotic myocardium (accumulation of Anx-
CLIO-Cy5.5) had evidence of necrosis (defined by delayed 
gadolinium enhancement) suggesting that the majority of 
apoptotic cardiomyocytes remain viable 4–6 hours after 
ischemia-reperfusion injury. This was confirmed on fluores-
cence microscopy and immunohistochemistry revealing the 
presence of large numbers of apoptotic, but potentially viable, 
cardiomyocytes in the “at-risk” area (AnxCLIO-Cy5.5 posi-
tive, Gd-DTPA-NBD negative areas). The authors remarked 
that strategies to salvage apoptotic, but not yet necrotic, 
myocardium should be explored now that these areas could 
be successfully imaged.
Carotid atherosclerosis
Carotid atherosclerosis and stroke are a major cause of dis-
ability and death. In the United States it is estimated that 
around 750,000 people become victims of stroke  annually.43 
Over one million Americans live with disabilities caused by 
stroke and 28% of strokes occur in people under the age of 
65.44
Although the traditional imaging marker of disease bur-
den has been stenosis, this is a poor marker of disease activity. 
It is now accepted that atherosclerosis is an inflammatory 
disorder45–47 involving recruitment of inflammatory cells 
into the lipid-rich plaque core. In atherosclerotic plaques, 
high macrophage density is a feature of vulnerability and 
correlates with risk of plaque rupture and clinical events.48 
Modern techniques are now able to assess the composition 
and pathobiology of the arterial wall itself, and identification 
of vulnerable plaques at high risk of rupture is therefore key. 
USPIO-enhanced MRI is well placed to evaluate inflamma-
tion within plaques and will be discussed in this section.
Kresse et al49 first demonstrated USPIO uptake in athero-
sclerosis in vivo. They administered atherosclerotic rabbits 
custom-made iron oxide nanoparticles, visualizing these on 
MRI and confirming histologically with Prussian Blue staining. 
This study was uncontrolled and no attempt was made at quan-
titative analysis. Ruehm et al50 soon followed this with a more 
robust protocol. They administered USPIO to hyperlipidemic 
atherosclerotic rabbits and performed MRI scans at multiple 
time points. They noted extensive but patchy signal voids along 
the length of the aortic wall in atherosclerotic rabbits, but not 
in controls. Aortae were harvested for histological assessment 
and electron microscopy. Hyperlipidemic rabbits given USPIO 
showed extensive iron deposition in the subintima demonstrated 
by Prussian Blue staining, and on electron microscopy, iron 
inclusions were noted within plaque macrophages.
Hyafil et al51 examined hypercholesterolemic rabbits fol-
lowing iatrogenic aortic injury from balloon angioplasty and 
conducted MRI sequences at various time points following 
ferumoxtran-10 administration. At 5 days post-infusion, signal 
voids were seen in injured aortae on in vivo MRI, extending both 
inward into the lumen and outward into the periaortic region 
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creating a “pseudostenosis” appearance. There was significantly 
more signal void in balloon-injured aortae  compared to control 
aortae (uninjured aortic regions or rabbits administered saline 
instead of USPIO). Regions of signal void correlated with 
iron and RAM-11 staining (a rabbit macrophage marker), and 
a close correlation was also noted between the distribution of 
iron and RAM-11 staining. Extensive histological iron staining 
was seen in the balloon-injured aortae.
The first demonstration of the feasibility of atherosclero-
sis imaging using USPIO in humans was reported by Schmitz 
et al52 in a small study of patients with pelvic malignancy 
undergoing MRI for assessment of lymphatic metastasis 
using the USPIO ferumoxtran-10, which was at the time 
licensed for this indication. They retrospectively examined 
the aortic bifurcation and detected new focal areas of subinti-
mal signal drop out in seven of 20 patients on T2*-weighted 
imaging that had not been present on the pre-USPIO images. 
The authors speculated that the presumed accumulation 
of subintimal USPIO was a consequence of dysfunctional 
endothelium and that this technique might function as an 
assay of endothelial integrity.
Kooi et al53 performed the first prospective human study 
evaluating atherosclerosis using USPIO (ferumoxtran-10) in 
a carotid endarterectomy model. Eleven patients scheduled to 
undergo carotid surgery following a symptomatic neurovascular 
event were imaged with T2*-weighted MRI at three time points: 
pre-USPIO, 24 and 72 hours post-USPIO. Semi-quantitative 
image analysis was undertaken by calculating the relative 
signal intensity in quadrants with visible signal changes and 
comparing to reference tissue (skeletal muscle). Following sur-
gery, carotid plaque was processed for immunohistochemical 
analysis and electron microscopy. Significant iron staining was 
noted in nine of ten plaques eligible for analysis, and regions 
co-localized with CD68 staining for macrophages. Electron 
microscopy confirmed this, demonstrating abundant USPIO-
sized intra-cytoplasmic inclusions within macrophages, which 
on energy-dispersive X-ray analysis were confirmed to be 
composed of iron. On magnetic resonance analysis, reduction 
in relative signal intensity was confined to areas of plaque that 
demonstrated positive histological iron staining. Maximum 
difference in pre- versus post-USPIO signal intensity occurred 
at 24 hours, with the 72 hour window failing to reach signifi-
cance, suggesting that this time point was too late to image 
USPIO uptake.
Trivedi et al54 conducted a small study of eight patients 
scheduled for carotid endarterectomy, performing multi-
sequence MRI at various time points (before, 24, 36, 48, and 
72 hours after ferumoxtran-10 administration). Only segments 
of plaque staining positive for iron revealed signal void on MRI 
which was clearest on qualitative review of the T2*-weighted 
images at the 36 and 48 hour time points. This finding was 
replicated in the quantitative analysis (employing relative sig-
nal intensity) revealing greatest relative signal loss between 24 
and 48 hours. Histological and electron microscopy analysis 
revealed most plaque sections demonstrated iron staining and 
that there was co-localization of iron and macrophage staining 
(MAC387), but there were regions with large populations of 
macrophages in the absence of iron staining. Electron micros-
copy confirmed the presence of USPIO-sized particles within 
macrophages.
In a subsequent study by the same authors,55 30 patients 
awaiting carotid endarterectomy for severe carotid stenosis 
were imaged before and 36 hours post-USPIO, in line with the 
findings of their previous work. MRI analysis was similar and 
more extensive histological validation was undertaken. Areas 
of reduced relative signal intensity were seen in 24/27 patients 
(three excluded for excessive artifact) that corresponded to 
USPIO/macrophage positive histology, and most samples 
(23/30) revealed iron staining within the plaque. There was 
a significant correlation between the presence of USPIO 
(based upon change in relative signal intensity) on MRI and 
iron staining in plaques with focal but not diffuse distribution 
of signal void. Co-localization of iron staining with CD68 
and MAC387 was seen but only modestly correlated (there 
were areas seen to stain for iron and not macrophages and 
vice versa), and in some sections there was extracellular iron 
staining around small neo-vessels, possibly indicating that 
these immature and leaky vessels may represent an entry 
port for USPIO.
The authors speculated that possible reasons for the 
weak correlation between iron and macrophage staining 
was a lack of sensitivity of Perls’ stain for USPIO, delayed 
kinetics of ferumoxtran-10 in inflammatory tissue, and that 
macrophage subtypes might have differing uptake kinetics 
for USPIO. This latter theory has been given some experi-
mental traction recently in a study which has shown that M1 
and M2 macrophages take up USPIO at different rates.56 
M1 polarized (pro-inflammatory/destructive) macrophages 
appear to take up relatively less USPIO than M2 polarized 
(anti-inflammatory/pre-healing) macrophages.
In 2006, Tang et al57 used a more objective analysis 
approach by calculating adjusted mean change in relative 
signal intensity. Instead of investigator selected regions of 
interest that are prone to bias, the mean change in relative 
signal intensity was calculated using multiple sample data 
points and a statistical model accounting for the correlation 
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between signal loss in different quadrants within a slice and 
different slices within a plaque. They recruited 20 patients 
due to undergo carotid surgery and compared symptomatic 
to contralateral asymptomatic carotid artery plaques (mean 
stenosis 77% versus 46% respectively). They found that 
all symptomatic plaques demonstrated signal void and 
interestingly, 19/20 patients displayed regions of inflamma-
tion on the contralateral asymptomatic side. Symptomatic 
lesions did, however, have a greater percentage of positive 
quadrants (72% versus 51%, P=0.007), and a significant 
reduction in adjusted mean relative signal intensity 
(10.9%±4.3%, P=0.02) that was not apparent on the con-
tralateral side. They also observed that, as seen in previous 
studies, several asymptomatic “stable” plaques actually 
showed enhancement (signal increase) in the fibrous cap. 
The authors concluded that the results demonstrate the 
systemic nature of atherosclerotic inflammation and that 
this technique may aid risk-stratification of asymptomatic 
plaques in the future.
The notion of systemic inflammation in atherosclero-
sis was explored further in another study by Tang et al.58 
Ten patients awaiting coronary artery bypass graft surgery 
for active coronary disease with incidental asymptomatic 
carotid stenosis (.50%) were compared to ten individuals 
with similar severity of asymptomatic carotid stenosis but 
no known coronary artery disease. Plaques from patients 
awaiting coronary artery bypass graft surgery showed a sig-
nificant mean signal intensity attenuation of 16.4% versus an 
increase (ie, enhancement) of 8.4% in the truly asymptomatic 
group making a true difference of 24.9% (95% confidence 
interval 16.7% to 33.0%; P,0.001) between groups. These 
data support the hypothesis that vascular inflammation is a 
systemic phenomenon measurable by USPIO accumulation 
and that signal enhancement may indicate a more stable 
plaque phenotype.
The same authors59 sought to clarify the relationship 
between traditional radiological markers of stroke risk and 
USPIO uptake in 71 individuals with asymptomatic carotid 
stenosis of varying severity. USPIO uptake on T2*W MRI 
was compared to luminal stenosis measurements of North 
American Symptomatic Carotid Endarterectomy Trial 
(NASCET)60 and European Carotid Surgery Trial (ECST)61 
methods, and normalized wall index. The group also made an 
attempt to model the USPIO data with respect to increasing 
stenosis severity. As with their previous work, no relation-
ship was evident between either measurement of stenosis 
severity and plaque inflammation, and both are independent 
risk factors providing valuable and completely different 
pathological information. To further assess this, a prospective 
trial examining outcome data in patients stratified by USPIO 
uptake would be required.
The ATHEROMA (Atorvastatin THerapy: Effects on 
Reduction Of Macrophage Activity) trial was designed 
to evaluate the effects of statin therapy on carotid plaque 
inflammation.62 Forty-seven patients with carotid stenosis of 
greater than 40% who demonstrated plaque USPIO uptake 
were randomized to low (10 mg) or high-dose (80 mg) 
atorvastatin for 12 weeks with USPIO-enhanced MRI at 
6 and 12 weeks. Twenty patients completed 12 weeks of 
treatment in each study arm. The primary end point was 
met with a significant reduction in USPIO uptake observed 
in the high-dose treatment arm at both 6 and 12 weeks. No 
such difference was evident in the low dose arm. Unsur-
prisingly, beneficial effects were noted on plasma lipid 
profiles but of greater interest was that microembolic load 
assessed by transcranial Doppler was significantly reduced. 
Furthermore, enhancement was seen in the fibrous cap and 
subintima in the high-dose but not the low-dose cohort, 
supporting previous observations that such enhancement 
may be associated with a more stable plaque phenotype. 
This study represents progress in developing a reliable 
imaging-based biomarker of atherosclerotic disease activity 
and inflammation. However, hard clinical outcomes are still 
lacking. Degnan et al63 performed a retrospective analy-
sis of all participants screened for the ATHEROMA trial 
(n=62) who received USPIO-enhanced MRI, and recorded 
the occurrence of stroke, transient ischaemic attack, MI or 
cardiovascular death during a median follow-up of 4 years. 
Although those who had events did appear to have greater 
mean change in relative signal intensity on MRI, there were 
small absolute differences that did not reach statistical sig-
nificance (P=0.07). When the population was divided into 
USPIO-positive or -negative plaque groups, survival curves 
did not diverge significantly. The authors conclude that their 
study was not powered to assess outcome but that there were 
perhaps encouraging signs emerging from the data.
Abdominal aortic aneurysms
Abdominal aortic aneurysms (AAAs) are defined as focal 
dilatations of the aorta, where aortic diameter is .1.5 times 
normal. They affect 5% of men over the age of 65, and within 
this group cause 2%–3% of deaths annually.64,65 The vast 
majority of these deaths occur as a result of aortic rupture, 
which has a mortality rate of 65%–85% even in those reaching 
hospital alive.66,67 Currently, aneurysm diameter alone is the 
sole parameter used to stratify risk, but up to a fifth of ruptured 
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AAAs have a diameter less than the 55 mm intervention 
threshold and many patients have larger aneurysms without 
symptoms.68,69 The implementation of aneurysm screening has 
reduced aneurysm-related mortality by up to 53%64 but will 
increase the number of patients under long-term surveillance. 
Due to the unpredictability and non-linearity of aneurysm 
growth, improvements to the prediction of aneurysm rup-
ture are required. Accordingly, there is a shift in focus from 
anatomical and morphological imaging to novel cellular and 
molecular techniques that evaluate lesion vulnerability on the 
basis of inflammatory and biological activity.
A prominent histological feature of AAAs is infiltration of 
T and B lymphocytes, macrophages, neutrophils, and natural 
killer cells.70–73 These inflammatory cells regulate the release 
of cytokines, resulting in the expression of cell adhesion mol-
ecules, protease production, and release of reactive oxygen spe-
cies that in turn cause degradation of the extracellular matrix 
through alterations in the balance of matrix metalloprotein ases 
and tissue inhibitors of matrix metalloproteinases.74,75 In addi-
tion, inflammation and hypoxia lead to new vessel formation 
and loss of vascular smooth muscle cells, and it is these 
mechanisms that predispose to aortic dilatation and increased 
risk of AAA rupture. Inflammation within the aortic wall is 
often focally distributed and it is these hotspots of pathological 
activity that have been the focus of much investigation.
Howarth et al were the first to report USPIO uptake in 
AAA in man. They described simultaneous USPIO uptake 
within atheroma of both the internal carotid artery and a 
56 mm, asymptomatic AAA.76 Truijers et al later described 
USPIO (ferumoxtran-10) uptake in the wall of a small num-
ber of asymptomatic AAAs (n=6).77 They found significantly 
more USPIO-positive quadrants in aneurysm patients than 
in age-matched controls, and the patient with the larg-
est number of USPIO-positive quadrants had the largest 
diameter aneurysm although there was a wide variation in 
USPIO uptake. A subsequent pilot feasibility study by Sadat 
et al (n=14) quantified USPIO uptake in the AAA wall by 
using calculated T2 and T2* values.78 They found significant 
correlation between imaging sequences pre- and 36 hours 
post-USPIO infusion, and both imaging methods were able 
to detect the presence of USPIO uptake.
Our group evaluated the potential for this technique to 
predict aneurysm expansion. Twenty-nine asymptomatic 
patients with AAAs underwent baseline MRI scans followed 
by intravenous administration of USPIO and repeat MRI 
scans 24–36 hours later. A similar technique was used to 
assess iron accumulation; the percentage change in T2* 
value was calculated following USPIO administration, but 
additionally, a threshold of significance for change was 
applied. By applying this threshold based on repeatability 
data for calculation of the T2* value in vascular tissue of 
subjects not receiving USPIO, we were able to distinguish 
changes in T2* associated with USPIO accumulation from 
artifact. All patients demonstrated non-specific peri-luminal 
USPIO accumulation, likely reflecting USPIO uptake in the 
fresh, highly cellular component of the thrombus. Thrombus 
within AAAs is structurally complex and is known to consist 
of a continuous network of interconnected canaliculi.79 This 
network may support transportation of inflammatory cells 
from lumen into the thrombus, and further into aortic wall as 
seen in some patients. Importantly, despite similar aneurysm 
sizes, it is these patients with mural USPIO uptake who had 
evidence of aneurysm growth rates three-fold higher (6.6 
mm/year) than patients with no mural USPIO uptake, sug-
gesting that this technique may be used to identify patients 
at greater risk of aneurysm growth. Aortic tissue was col-
lected from patients undergoing open surgical aneurysm 
repair and histological analysis confirmed co-localization 
A
%∆T2* value
100
90
80
70
60
50
40
30
20
10
0
B C
Figure 3 T2*-weighted color maps showing alongside the corresponding T2-weighted anatomic images from patients with abdominal aortic aneurysms (AAA).
Notes: The color scale represents the magnitude of the change in T2* value, with blue indicating minimal change and red indicating a large change in T2* value using a 
previously defined threshold above which changes in T2* value can be attributed to ultra-small superparamagnetic particles of iron oxide (USPIO) accumulation. Only changes 
in T2* value above the threshold are presented on the graduated (yellow-red) color scale; data below the threshold appear blue. (A) shows a change in T2* value confined 
to the peri-luminal area; (B) diffuse patchy changes in T2* throughout the intraluminal thrombus but no distinct focal area of USPiO uptake affecting the aortic wall; and (C) 
discrete focal area of USPiO uptake involving the wall of the AAA that is distinct from the peri-luminal region.
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of USPIO with CD68 staining for macrophages.80 An 
observational surveillance study is currently underway 
in our center (MA3RS study) examining whether USPIO-
enhanced MRI is able to predict the likelihood of rupture 
or need for surgery (Figures 3 and 4).
Conclusion and future applications
USPIO can detect inflammation in cardiac, carotid, and 
aortic disease, whilst providing targeted imaging in stem 
cell therapy and apoptosis. It is a technique that holds major 
promise for translation into the clinic.
The development of iron nanoparticle-enhanced MRI 
has been greatly affected by the discontinuation of several 
agents in recent years. Ferumoxtran-10 (Sinerem®), was 
discontinued due to a high false-positive rate of detecting 
lymph node metastasis in patients with prostate cancer.81 
NC100500 (Clariscan™) was discontinued over concerns 
regarding long-term liver retention,82 and the larger SPIO fer-
umoxides (Feridex® in United States, Endorem™ in Europe), 
and ferucarbotran (Resovist®) have also been discontinued; 
the latter two agents were the only two clinically approved 
SPIO agents for MRI. At present there is only one iron oxide 
particle preparation available for clinical use:  ferumoxytol 
(Rienso®; Takeda Italia S.p.A, Rome, Italy), a 17–30 nm 
USPIO. Rienso is marketed for the intravenous treatment of 
iron deficiency anemia in adult patients with chronic kidney 
disease, but is currently not licensed for imaging.
There are several clear opportunities for the develop-
ments of USPIO-enhanced MRI as a clinical research tool 
and our group is using ferumoxytol-enhanced MRI success-
fully in several clinical research studies. We are attempting 
to characterize myocardial inflammation following MI in 
humans: using the assessment of cellular myocardial inflam-
mation as a biomarker for therapeutic interventions. We are 
also piloting USPIO-enhanced MRI as a diagnostic test in 
other inflammatory myocardial diseases such as sarcoidosis 
and myocarditis. At the same time, we are exploring whether 
USPIO-enhanced MRI can identify patients with high-risk 
atherosclerotic plaques and AAAs who require early medical 
or surgical intervention. There are also clear opportunities 
for USPIO-enhanced MRI in the development of stem cell 
therapy.
It is difficult to predict where USPIO-enhanced MRI 
will make a breakthrough into clinical practice but there 
are clear applications in a range of cardiovascular and non-
cardiovascular diseases. This exciting imaging technique 
has great potential and results of research studies in coming 
years will determine its place in the clinic.
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